ALLOS PHARMA
We are a global team dedicated to improve the lives of patients with Fragile X Syndrome and Autism Spectrum Disorder. Our work spans three decades of research in neuroscience and intellectual disabilities. The “mGluR theory of fragile X” proposed by MIT Professor Mark Bear and collaborators in 2004 is widely considered to be a key conceptual breakthrough, and laid the foundation for development of disease-modifying therapies for treatment of Fragile X Syndrome and Autism Spectrum Disorder. Allos Pharma is committed to develop and market the first approved therapy in Fragile X Syndrome.
ALLOS PHARMA
Industry:
Health Care Life Science Medical Neuroscience Pharmaceutical
Founded:
2019-01-01
Website Url:
http://www.allospharma.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Technology used in webpage:
Gravatar Profiles Danish Server Location
Similar Organizations
dRx Capital
Novartis Digital Health Venture Capital
Estro technologies s.r.l.
Technologies for neurodevelopmental disorders
Genevant
Delivering solutions through RNA therapeutics.
GreenCom
We make our future green and safe.
Instapill
Wholesale Over The Counter Naturals
Neurochlore
Neurochlore develops therapeutic method to treat developmental brain disorders.
Palo Santo Fund
Palo Santo Fund is an investment fund that invests in psychedelic and healthcare industry.
Sensus Drug Development Corporation
Sensus Drug Development Corp.
Current Employees Featured
Official Site Inspections
http://www.allospharma.com
- Host name: webcluster1.webpod17-cph3.one.com
- IP address: 46.30.215.134
- Location: Copenhagen Denmark
- Latitude: 55.6786
- Longitude: 12.5589
- Timezone: Europe/Copenhagen
- Postal: 1052
More informations about "Allos Pharma"
ABOUT – Allos Pharma
We are a global team dedicated to improve the lives of patients with Fragile X Syndrome and Autism Spectrum Disorder. Our work spans three decades of research in neuroscience and … See details»
Allos Pharma - Crunchbase Company Profile & Funding
88 Save Actions Pioneering Therapeutics for Neurodevelopmental Disorders Founded 2019 Private 1-10 allospharma.com Health Care Life Science Medical See details»
Allos Pharma Company Profile | Management and Employees List
Find contact information for Allos Pharma. Learn about their Pharmaceuticals, Manufacturing market share, competitors, and Allos Pharma's email format. See details»
Allos Pharma - 2025 Company Profile & Competitors - Tracxn
Jun 14, 2025 Allos Pharma is an unfunded company based in Switzerland, founded in 2019. It operates as a Developer of therapeutics for neurological disorders. Allos Pharma has not … See details»
Allos Pharma - Overview, News & Similar companies | ZoomInfo.com
View Allos Pharma (www.allospharma.com) location in United States , revenue, industry and description. Find related and similar companies as well as employees by title and much more. See details»
Allos Pharma, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Explore Allos Pharma, Inc. with its drug pipeline, therapeutic area, technology platform, 3 news, and 1 literature. See details»
Allos Pharma Information - RocketReach
Allos Pharma is a Pharmaceutical Manufacturing, Health Care, and Life Science company with 2 employees. Find top employees, contact details and business statistics at RocketReach. See details»
Allos Pharma – Late-stage Pharmaceutical Company
Allos Pharma is committed to delivering science-based treatments for underserved neurodevelopmental and neurological disorders. Arbaclofen is the first therapy to show replicated improvements in social functioning and … See details»
Allos Pharma - VentureRadar
Allos Pharma Inc. is a biopharmaceutical company dedicated to the development of treatments for rare neurological disorders. Allos’ investigational drug, arbaclofen, is currently in Phase 3 … See details»
Allos Pharma company information, funding & investors
Jan 1, 2019 Allos Pharma, late-stage pharmaceutical company | allos pharma. Here you'll find information about their funding, investors and team. See details»
Allos Pharma Inc. Expands Intellectual Property Rights for Arbaclofen
Sep 18, 2023 Allos also announces today the worldwide exclusive rights to granted patents and clinical programs for arbaclofen in further indications, including Autism Spectrum Disorder. … See details»
Allos Pharma - Company Information, Competitors, News & FAQs
Find useful insights on Allos Pharma's company details, tech stack, news alerts, competitors and more. Use 6sense to connect with top decision-makers at Allos Pharma. See details»
Allos Pharma, Inc.:Company Profile & Technical …
Discovery Company profile page for Allos Pharma, Inc. including technical research,competitor monitor,market trends,company profile& stock symbol See details»
Allos Pharma Inc. Receives FDA Guidance for the Design of a …
CAMBRIDGE, Mass., May 23, 2023 /PRNewswire/ — Allos Pharma Inc. (“Allos”), a biopharmaceutical company specializing in the development of treatments for rare … See details»
Allos Pharma Inc. - BioCentury Company Profiles - BCIQ
Apr 25, 2022 Allos Pharma Inc. - BioCentury Company Profiles for the biopharma industry See details»
Allos Pharma Revives Arbaclofen After 7 Years: New Hope for …
Nov 19, 2020 Experience the revival of arbaclofen as Allos Pharma Inc launches a new development program, providing renewed hope for the Fragile X community. Discover the … See details»
Allos Pharma Inc. Receives FDA Guidance for the Design of a …
May 23, 2023 /PRNewswire/ -- Allos Pharma Inc. ("Allos"), a biopharmaceutical company specializing in the development of treatments for rare neurological disorders,... See details»
Allos Pharma Inc. presents new positive data analyses at the 18th …
CAMBRIDGE, Mass., July 14, 2022 /PRNewswire/ — Allos Pharma Inc (“Allos”), a late-stage pharmaceutical company developing therapeutics for neurodevelopmental disorders, … See details»
News – Allos Pharma
Allos Pharma Inc. presents new positive data analyses at the 18th NFXF International Fragile X Conference By Allospharma Allos See details»
Allos Pharma Inc. Receives FDA Guidance for the Design of a …
May 23, 2023 Allos Pharma Inc. ("Allos"), a biopharmaceutical company specializing in the development of treatments for rare neurological disorders, announced today that it has held a … See details»